» Articles » PMID: 32002162

A Case of Multisystem Langerhans Cell Histiocytosis Presenting As Central Diabetes Insipidus

Overview
Date 2020 Feb 1
PMID 32002162
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Langerhans cell histiocytosis (LCH) is a rare malignancy most commonly characterized by histiocytic infiltration of bone. LCH lesions in the skull place the adjacent central nervous system (CNS) at risk for involvement, which can manifest as central diabetes insipidus (CDI) when there is infiltration of the hypothalamic-pituitary axis. We present a case of a 39-year-old female who presented with polyuria and polydipsia for 1 year and left-sided hearing loss, gait instability, and nystagmus for 5 days. She was found on laboratory evaluation to have CDI and underwent left cortical mastoidectomy for a destructive peripherally enhancing mastoid lesion seen on MRI brain. Pathology revealed CD1a and S100+ LCH and the patient was subsequently discharged to begin outpatient chemotherapy with vinblastine and prednisone. The patient's CDI was diagnostic of CNS involvement, making her LCH multisystem through the infiltration of both the skull and hypothalamic-pituitary structures. As CDI can be seen in up to 25% of single-system LDH, and up to 50% of multisystem cases, radiologic studies to evaluate for osteolytic skull lesions must be considered as part of the evaluation for LCH when CDI has been diagnosed.

Citing Articles

Langerhans Cell Histiocytosis With Hypothalamic-pituitary and Bone Involvement: A Report of 2 Cases.

Giraldi E, Allen J, McLemore M, Ioachimescu A JCEM Case Rep. 2025; 3(3):luaf017.

PMID: 39935495 PMC: 11809238. DOI: 10.1210/jcemcr/luaf017.


A rare imaging presentation with multisystemic clinicopathological features of Langerhans cell histiocytosis: Case report and literature review.

Li X, Wang Y, Liu Q, Zeng Q, Fu H, He J Medicine (Baltimore). 2023; 102(35):e34881.

PMID: 37657004 PMC: 10476768. DOI: 10.1097/MD.0000000000034881.


Adult Langerhans Cell Histiocytosis Diagnosed by Biopsy of the Skull Tumor Generated after Craniotomy.

Kono M, Inomoto C, Horiguchi T, Sugiyama I, Nakamura N, Saito R NMC Case Rep J. 2021; 8(1):101-105.

PMID: 34012758 PMC: 8116926. DOI: 10.2176/nmccrj.cr.2020-0094.

References
1.
Berres M, Lim K, Peters T, Price J, Takizawa H, Salmon H . BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014; 211(4):669-83. PMC: 3978272. DOI: 10.1084/jem.20130977. View

2.
Grois N, Fahrner B, Arceci R, Henter J, McClain K, Lassmann H . Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010; 156(6):873-881.e1. DOI: 10.1016/j.jpeds.2010.03.001. View

3.
Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A . A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001; 138(5):728-34. DOI: 10.1067/mpd.2001.111331. View

4.
Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M . Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013; 121(25):5006-14. DOI: 10.1182/blood-2012-09-455774. View

5.
Emile J, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J . Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016; 127(22):2672-81. PMC: 5161007. DOI: 10.1182/blood-2016-01-690636. View